Skip to main content

Pharmacogenetics: Opportunities and Challenges for Health Innovation: (Complete Edition ‐ ISBN 9789264076808)

Buy Article:

$32.00 plus tax (Refund Policy)


Pharmacogenetics helps us understand the relationship between an individual's genetic make‐up and the way medicines work for each person. This book reviews the use of pharmacogenetics across all stages of the health innovation cycle from research through to uptake by doctors and patients. It focuses on how to optimise the use of pharmacogenetics to deliver effective innovations for public health, and design policies that enhance their economic and social benefits. The book argues for large‐scale studies to validate the biomarkers that underpin pharmacogenetics and policies to share the cost and risk of using  pharmacogenetics to improve the use of existing   medicines. Governments and others need to align regulatory, reimbursement and other incentives and work  with industry to measure better the impacts of pharmacogenetics. Health systems need to take positive steps to adapt to the use of pharmacogenetics and ensure that health professionals receive adequate training. For related or other OECD work in this area, see .

Pharmacogenetics: Opportunities and Challenges for Health Innovation is part of the OECD Innovation Strategy, a comprehensive policy strategy to harness innovation for stronger and more sustainable growth and development, and to address the key societal challenges of the 21st century. For more information about the OECD Innovation Strategy, see .

  ‐ Acronyms

  ‐ Executive Summary

  ‐ Introduction to the Policy issues

  ‐ The Supporting Infrastructures for Pharmacogenetics

  ‐ Pharmacogenetics and Drug Development

  ‐ Business Models for Pharmacogenetics

  ‐ Physician and Patient Demand for Pharmacogenetics

  ‐ Regulatory Authorities and Reimbursement Mechanisms

  ‐ Conclusions

Keywords: biomedicine; business models; diagnostics; drug development; genetic testing; health care; innovation; personalised medicine; pharmaceuticals; pharmacogenetics; pharmacogenomics; regulatory policy; reimbursement policies; research and development

Document Type: Review Article

Publication date: 2009-11-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more